In 2012, Biotech IPOs Continue Their Inside Story
This article was originally published in Start Up
Executive Summary
Among the new realities for life science VCs, from structured acquisitions to no-go therapeutic areas, it looks like we can add insider participation in IPOs to the list. It's been nearly a year since a life-science company went public in the US without its private investors pitching in.
You may also be interested in...
As Some VCs Run On Empty, Others Are Topping Off The Tank
New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.